SELLAS Life Sciences Group financials
$11.51−0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$10.6M | -$9.3M | -$8.3M | -$7.1M | -$6.9M | -$6.1M | -$6.9M | -$7.3M | -$7.6M | -$9.6M | -$8.2M | -$9.4M |
| Net income | -$9.6M | -$8.4M | -$7.7M | -$6.8M | -$6.6M | -$5.8M | -$6.7M | -$7.1M | -$7.5M | -$9.6M | -$8.1M | -$9.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.09 | $-0.10 | $-0.13 | $-0.21 | $-0.26 | $-0.33 |
| EBITDA | -$10.6M | -$9.3M | -$8.3M | -$7.1M | -$6.9M | -$6.1M | -$6.9M | -$7.3M | -$7.6M | -$9.6M | -$8.2M | -$9.4M |
| Operating cash flow | -$7.6M | -$8.8M | -$4.9M | -$7.1M | -$7.3M | -$9.1M | -$7.2M | -$7.8M | -$9.7M | -$10.8M | -$4.8M | -$6.9M |
| Free cash flow | -$7.6M | -$8.8M | -$4.9M | -$7.1M | -$7.3M | -$9.1M | -$7.2M | -$7.8M | -$9.7M | -$10.8M | -$4.8M | -$9.4M |
| Diluted shares | 189.2M | 172.5M | 141.5M | 108.4M | 98.6M | 87.8M | 74.1M | 68.3M | 57.6M | 44.8M | 30.9M | 28.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $138.3M | $107.1M | $71.8M | $44.3M | $25.3M | $28.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $145.4M | $114.2M | $78.3M | $51.6M | $32.3M | $35.0M |
| Total liabilities | $7.7M | $6.8M | $7.5M | $5.9M | $6.2M | $7.2M |
| Shareholders' equity | $137.7M | $107.4M | $70.9M | $45.6M | $26.1M | $27.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology